Department of Gynecology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Curr Oncol. 2024 Aug 30;31(9):5107-5120. doi: 10.3390/curroncol31090378.
Ovarian mesonephric-like adenocarcinoma (MLA) is a newly described histological type known for its aggressive behavior. This study aims to determine the frequency of ovarian MLA, review the existing literature, and elucidate its clinicopathological characteristics, including the potential therapeutic targets.
We retrospectively reviewed the pathological diagnoses of 501 primary ovarian cancer surgical cases at our institution from 2010 to 2023. MLAs exhibiting typical morphological and immunohistochemical features were included. The frequency and clinicopathological characteristics of these cases were summarized. Additionally, we conducted a literature search using PubMed to collect and summarize previously reported cases of ovarian MLAs.
Among the 501 primary ovarian cancer cases, we identified 3 cases (0.6%) of MLA. The patients were 52-76 years old, and the initial FIGO stages were IC1 (two cases) and IIIB (one case). All the cases exhibited HRP, pMMR, PD-L1 negativity (CPS < 1), and low HER2 expression. Two cases experienced metastatic recurrence. A literature review identified 97 cases of MLA. The MLAs frequently exhibited mutations (90%, 38/42), with a recurrence rate of 39% (26/67).
MLAs accounted for 0.6% of malignant ovarian tumors at our institution, all of which were advanced or recurrent cases. These cases showed HRP, pMMR, and PD-L1 negativity, indicating a lack of current therapeutic targets. The literature also reported a high incidence of advanced and recurrent cases, highlighting the need for accurate diagnosis and the development of new treatments. The frequent mutations suggest a potential therapeutic target for recurrent or metastatic MLA.
卵巢中肾样腺癌（MLA）是一种新描述的组织学类型，以侵袭性行为而闻名。本研究旨在确定卵巢 MLA 的频率，回顾现有文献，并阐明其临床病理特征，包括潜在的治疗靶点。
我们回顾性分析了 2010 年至 2023 年我院 501 例原发性卵巢癌手术病例的病理诊断。纳入具有典型形态学和免疫组织化学特征的 MLA。总结这些病例的频率和临床病理特征。此外，我们使用 PubMed 进行文献检索，收集和总结以前报道的卵巢 MLA 病例。
在 501 例原发性卵巢癌病例中，我们发现 3 例（0.6%）为 MLA。患者年龄为 52-76 岁，初始 FIGO 分期分别为 IC1（2 例）和 IIIB（1 例）。所有病例均表现为 HRP、pMMR、PD-L1 阴性（CPS<1）和低 HER2 表达。2 例发生转移性复发。文献复习共发现 97 例 MLA。MLA 常表现为 突变（90%，38/42），复发率为 39%（26/67）。
在我们的机构中，MLA 占恶性卵巢肿瘤的 0.6%，均为晚期或复发性病例。这些病例表现为 HRP、pMMR 和 PD-L1 阴性，表明目前缺乏治疗靶点。文献报道晚期和复发性病例发生率较高，这突显了准确诊断和开发新治疗方法的必要性。频繁的 突变提示复发或转移性 MLA 可能存在潜在的治疗靶点。
